Lightnews — Scholar-powered news

0 followers 0 following 0 posts

Videos

Economics 51%

Public Health 19%

Posts Media Videos Starter Packs

Reposted by Martin McKee, Lotte Steuten

Carl Ott, Author @bubba687.bsky.social · Jul 11

300 3.9K 18K

Reposted by Lotte Steuten, Paula Lorgelly

Prof Nancy Devlin @prof-nancy-devlin.bsky.social · Jul 11

Will Trump's plan to use 'Reference Pricing' cut US drug prices? This #ValueinHealth paper by Grueger, Martin & Sullivan argues reference pricing is ill-advised & will lead to unintended consequences.

open access 👉 tinyurl.com/reference-pr...

#Trump #HealthEconomics

Image is copyright to Jane Doe/ Shutterstock. Shows a cartoon image of Donald Trump with a signed Executive Order

1 2 2

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Jun 12

There is a range of ways ex-US payers and pharma companies might respond to President Trump’s “Most Favoured Nation” drug pricing. Will any of them work to lower #US drug prices?

Read more: www.ohe.org/insight/the-trump-administrations-us-drug-pricing-proposal-what-will-happen-next/

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Jun 11

New insight: 68% of OECD countries formally use #QALYs in pricing decisions, but practices vary. How consistent is economic evaluation across borders?
www.ohe.org/insight/how-...

#HTA #healtheconomics

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Jun 9

Argentina plans a new national #HTA agency, ANEFiTS. A big step for evidence-based #policy, but key questions on governance, transparency & legal power remain. Read more: www.ohe.org/insight/arou...

2 1

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Jun 5

New insight: a substantial proportion of these medicines do not deliver their intended therapeutic benefits for the individuals taking them, due to genetic variations.
##pharmacogenomics #CERSI

www.ohe.org/insight/pharmacogenomics-testing-a-crucial-piece-to-unlocking-the-full-value-of-medicines/

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Jun 5

Vaccines return up to 19x their cost, but adult #immunisation is undervalued. Our new insight calls for long-term investment to boost health, productivity & system resilience. www.ohe.org/insight/prevention-pays-off-so-why-arent-we-doing-more-of-it/

1 1

Reposted by Lotte Steuten

The Commonwealth Fund @commonwealthfund.org · May 21

Proposals to dramatically cut #Medicaid funding could put the health and lives of nearly 24 million women at risk.

Medicaid Cuts Could Increase Maternal Mortality and Jeopardize Women’s Health

Proposals to dramatically cut Medicaid funding could put the health and lives of nearly 24 million women at risk.

www.commonwealthfund.org

10 7

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · May 20

How can the #UK prepare for an #ageingsociety? OHE’s submission to a #parliamentary inquiry stressed that keeping as many people as healthy and productive as possible – for as long as possible – is a requisite measure in addressing a shrinking #workforce. Read more: www.ohe.org/insight/offi...

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · May 19

Kenya is making progress on using evidence to guide healthcare decisions. New reforms embed #HTA in #policy, but challenges in capacity, funding and transparency remain. www.ohe.org/insight/arou...

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · May 12

GLP-1s are changing #obesity care—but access, equity, and patient preferences raise new challenges. Our latest insight looks at what this means for #policy and practice. www.ohe.org/insight/glp-...

#healtheconomics #GLP1

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · May 8

📢 New publication from OHE: Understanding the full value of long-acting therapies: Less is more?

We will also be discussing this research at ISPOR 2025 in Issue Panel 116. Join us for the discussion!

Read it here: www.ohe.org/publications...

#healtheconomics #HTA

Understanding the Full Value of Long-Acting Therapies: less is more? - OHE

Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, real-world evidence, and policy needs.

www.ohe.org

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · May 6

47% of NICE “positive” decisions now limit treatment to just 31% of eligible patients. A new OHE report looks at the rise in ‘optimised’ guidance—and what it means for patient access.
www.ohe.org/publications...

#HTA

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 28

Respiratory infections can cost UK businesses £44 billion a year—but how much is your company losing? Use the new Cost Calculator from OHE & funded and owned by Pfizer to get a tailored estimate and consider the impact on productivity. Try it now: www.ohe.org/respiratory-...
#HealthEconomics

Respiratory Cost Calculator - OHE

The Respiratory Cost Calculator summarises the potential financial impacts of employee absenteeism and presenteeism as incurred by the employer due to respiratory infections.

www.ohe.org

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 16

From the Archives: Our report, published at April 2024, looked at how HTA methods have evolved across 14 countries, highlighting key reforms, guidance gaps, and the role of international collaboration in shaping future approaches. Find out more: www.ohe.org/publications...
#HTA #healtheconomics

How Have HTA Agencies Evolved Their Methods Over Time? - OHE

This report explores the variation in past and current positioning of Health Technology Assessment (HTA) agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient...

www.ohe.org

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 15

New report: Analysing Global Immunisation Expenditure

Immunisation is critical for public health, but funding remains low. Our latest report reveals key trends in investment, preventable mortality & coverage.
www.ohe.org/publications...

#Immunisation #PublicHealth #HealthEconomics #Vaccines

3 1 3

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 14

Read the key takeaways here: www.ohe.org/publications...

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region - OHE

OHE’s BRAVER Roadmap outlines how adopting a societal perspective in HTA can improve equity, innovation, and health outcomes in the Asia-Pacific region.

www.ohe.org

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 14

We recommend a gradual adoption, international collaboration, and patient involvement to drive meaningful change. #HTA #HealthEconomics

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 14

The adoption of a societal perspective in HTA can help addressing societal and economic needs in the Asian-Pacific region, but its implementation is limited. Barriers include the lack of methods and evidence and capacity constraints. #HTA #HealthEconomics

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

2 1 1

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 10

Should cognition be added to EQ-5D? New research by OHE's Hannah Hussain explores whether memory & concentration perform better than a single “cognition” item. Findings could reshape EQ-5D use in dementia, mental health & HTA. www.ohe.org/insight/addi...

1 1

Reposted by Lotte Steuten

Office of Health Economics @ohenews.bsky.social · Apr 9

Canada’s HTA system blends provincial autonomy with national coordination. CDA-AMC’s evolving role and the pan-Canadian Pharmaceutical Alliance are reshaping drug access and pricing. Future reforms, including national Pharmacare and global collaboration, promise more efficient and patient access.

1 3 2

Reposted by Lotte Steuten

Beth Popp Berman @epopppp.bsky.social · Feb 20

Another way to put this:

Musk and his twerps have exposed us to pandemics, broken science, stolen all your data, endangered the U.S. payments system, threatened air traffic control, and cut off HIV medication to 20m people in order to save ::checks notes:: 2/10th of a percent of the federal budget.

Bloomberg News @bloomberg.com · Feb 19

DOGE says it has saved $55 billion in federal spending so far, but its website only accounts for $16.6 billion of that

DOGE Says It’s Saved $55 Billion, Itemized Data Show Far Less

The federal cost-cutting effort dubbed the Department of Government Efficiency says it has saved $55 billion in federal spending so far, but its website only accounts for $16.6 billion of that.

www.bloomberg.com

67 1.5K 3.6K

Reposted by Lotte Steuten

David Shaywitz @dshaywitz.bsky.social · Feb 16

Great op-ed by @cmyeaton.bsky.social on the surprisingly high level of popular support vaccines continue to enjoy - www.nytimes.com/2025/02/16/o... - almost as if most people prefer them to polio, measles, and cervical cancer. Also: my @wsj.com review of her recent book-> www.wsj.com/arts-culture...

Opinion | Kennedy’s Anti-Vaccine Views Don’t Represent America

Threatening vaccine access is not only bad science, it’s bad politics.

www.nytimes.com

15 42

Reposted by Cary P. Gross, Lotte Steuten, Jane E. Fountain , and 1 more Cary P. Gross, Lotte Steuten, Jane E. Fountain, Andrew R. Morral

Megan Ranney MD MPH @meganranney.bsky.social · Feb 15

🛟 That last-ditch chemo trial your family member was hoping to be in
🥙 The investigation of a food-borne illness outbreak in the next town over
🧠The study looking for preventable causes of Alzheimer’s
🧪The assurance that TAXPAYER-PAID-FOR studies & data collection see the light of day

47 850 2.8K